Dr. Bekaii-Saab on Sequencing Regorafenib and TAS-102 in CRC

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses sequencing regorafenib and TAS-102 for the treatment of patients with colorectal cancer (CRC).

Phase III data from two separate clinical trials, RECOURSE and CORRECT, support the efficacy of oral targeted therapy regorafenib and cytotoxic agent TAS-102, Bekaii-Saab explains. However, neither study specifically examined TAS-102 prior to treatment with regorafenib.

In clinical practice, patients first receive regorafenib and, upon progression, are administered TAS-102. However, if a patient has liver function abnormalities or hand-foot syndrome, TAS-102 may be moved ahead of regorafenib in the therapy sequence. Patients who experience significant bone marrow toxicities are less likely candidates to receive TAS-102 upfront, Bekaii-Saab adds.

<<<

View more from the 2016 GI Cancer Symposium